首页 | 本学科首页   官方微博 | 高级检索  
     


Chromosomal Alterations and Gene Expression Changes Associated with the Progression of Leukoplakia to Advanced Gingivobuccal Cancer
Authors:Priyanka G. Bhosale  Simona Cristea  Srikant Ambatipudi  Rajiv S. Desai  Rajiv Kumar  Asawari Patil  Shubhada Kane  Anita M. Borges  Alejandro A. Schäffer  Niko Beerenwinkel  Manoj B. Mahimkar
Affiliation:2. Homi Bhabha National Institute, Training School Complex, Anushakti Nagar, Mumbai, 400085, India;3. Department of Biosystems Science and Engineering, ETH Zurich, 4058, Basel, Switzerland;4. SIB Swiss Institute of Bioinformatics, 4058, Basel, Switzerland;5. MRC Integrative Epidemiology Unit, University of Bristol, BS8 1TH, UK;11. Department of Pathology & Laboratory Medicine, S. L. Raheja Hospital, Mumbai, 400016, India;12. Computational Biology Branch, National Center for Biotechnology Information, National Institute of Health (NIH), Department of Health and Human Services (DHHS), Bethesda, MD, 20894, USA
Abstract:We present an integrative genome-wide analysis that can be used to predict the risk of progression from leukoplakia to oral squamous cell carcinoma (OSCC) arising in the gingivobuccal complex (GBC). We find that the genomic and transcriptomic profiles of leukoplakia resemble those observed in later stages of OSCC and that several changes are associated with this progression, including amplification of 8q24.3, deletion of 8p23.2, and dysregulation of DERL3, EIF5A2, ECT2, HOXC9, HOXC13, MAL, MFAP5 and NELL2. Comparing copy number profiles of primary tumors with and without lymph-node metastasis, we identify alterations associated with metastasis, including amplifications of 3p26.3, 8q24.21, 11q22.1, 11q22.3 and deletion of 8p23.2. Integrative analysis reveals several biomarkers that have never or rarely been reported in previous OSCC studies, including amplifications of 1p36.33 (attributable to MXRA8), 3q26.31 (EIF5A2), 9p24.1 (CD274), and 12q13.2 (HOXC9 and HOXC13). Additionally, we find that amplifications of 1p36.33 and 11q22.1 are strongly correlated with poor clinical outcome. Overall, our findings delineate genomic changes that can be used in treatment management for patients with potentially malignant leukoplakia and OSCC patients with higher risk of lymph-node metastasis.
Keywords:Address all correspondence to: Manoj B. Mahimkar   Cancer Research Institute (CRI)   Advanced Centre for Treatment   Research and Education in Cancer (ACTREC)   Tata Memorial Centre (TMC)   Navi Mumbai   410210   India.
本文献已被 ScienceDirect 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号